Panelists:
Lloyd Jeffs, PhD
Strategic Customer Leader
Cytiva
Adam Crowe, PhD
Senior Analytical Development Manager
Cytiva
Felix Yuen
Senior Manager, Process Development Services
Cytiva
Sandra Racordon-Pape, PhD
Head of Regulatory Science and Strategy
Cytiva
- Time:
In the dynamic world of mRNA lipid nanoparticle (mRNA-LNP) technology, scientists are quickly moving beyond infectious disease vaccines into a range of new modalities and applications. However, the intricate nature of mRNA-LNP therapeutics poses unique challenges for research and manufacturing including issues with scalability, process control, batch consistency, and more. Cytiva’s tailored outsourcing strategies are designed to help scientists navigate through these complexities in ways that mitigate risks and accelerate the development of promising drug candidates for clinical evaluation and successful commercialization.
In this GEN webinar, three experts in nanomedicine will share insights into critical aspects of mRNA-LNP formulation, process development, and novel analytical methods that will help shape the future of therapeutics development. You’ll learn how Cytiva’s scientists are scaling operations to meet GMP manufacturing standards and keeping pace with the evolving regulatory landscape of nanomedicines. During the discussion, panelists will explore:
- Innovations in formulation, analytics, and bioassays
- Best practices for downstream process development and efficient scale-up
- Strategies for achieving GMP manufacturing excellence
- Navigating regulatory considerations with foresight and agility
A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.
Produced with support from:
